Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
A good buy today Chester, although the market will probably disagree tomorrow.
Surprised, would you expect an update when the next payment is received, or do you think it'll be saved for the next financials? I suppose it's material information.
I meant good value for us to top-up rather than for a takeover :)
We've seen significant drops here, and everywhere, and I think there's far, far more to come globally and not just for the short-term.
But when you look at the value of the business, £27 million is very low already. Cash and cash equivalents in September were £21 million.
They were good, well informed, questions weren't they. I'd like to have heard more.
With the planned expansion of the Phase I/IIa studies, it looks like we'll skip Phase IIb and go straight to Phase III. Hopefully we can skip the pandemic part too.
Michael Hunt at the Shares Magazine Investor Evening a week or so ago:
https://www.sharesmagazine.co.uk/video/reneuron-group-rene-michael-hunt-cfo-2
Chester, Michael Hunt did say relatively recently that it wouldn't be inconceivable to get the products to market on their own. Agreed though that there are probably potential partners waiting for the data, and hopefully willing to pay a high price.
Every positive dataset adds intrinsic value. The market values ReNeuron less now than after the Fosun deal, and yet we're closer to the next partnership deal. Perhaps Coronavirus doesn't help, but when the warm weather comes and that clears off hopefully 150p will be a distant memory.
It would be interesting to see the individual patient results rather than mean improvements.
But then what would be more impressive, all patients having a 3 line improvement, or some patients significantly more and some less?
I've just been scanning YouTube for Michael Hunt's latest Shares Magazine Investor Evening presentation, that hasn't been uploaded yet, but I did see this from 6 months ago. I presume it's a genuine source: https://youtu.be/i2xK3Ls0jFU
They're at the International Stroke Conference in 2 weeks, so perhaps a progress update around then, although I suspect we won't hear much in the way of results until the top-line read-out in mid-2021.
For hRPC, I'd keep a look out for attendance at a US-based medical event, perhaps AAO 2020 in November.
Probably better to have a full data set rather than piece by piece, if the effects of the previous update are anything to go by.
Sold half my holding this morning.
I read this a few years ago and have since been very concious of the dewatering progress and aquifer strength. Haven't had an update as yet that has resolved my concern:
'Water rates should peak within the first few years and decline thereafter, unless the aquifer is extremely strong or the number/spacing of producing wells is insufficient to depressure the reservoir.'
From https://petrowiki.org/PEH:Coalbed_Methane
As referred to below:
https://www.investorschronicle.co.uk/shares/2020/01/16/picking-merger-winners/
Without wanting to get ahead of myself, £15/share, or approximately £480 mln, would significantly undervalue the near and mid-term potential, in my view. Partnering deals will give a big boost, successful trials a massive boost.